Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

33.7K
Overview
33.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Forecasting virus evolution by integrating genotype-phenotype-epidemiology.

Nature microbiology·2026
Same author

Stabilizer Orthosis Rehabilitation after Bilateral Hip Disarticulation Due to Necrotizing Fasciitis: A Case Report and Literature Review.

Progress in rehabilitation medicine·2026
Same author

Genetic diversity of pangolin coronaviruses reveals a key immuno-evasive substitution at spike residue 519.

Journal of virology·2026
Same author

Programmable antibody-based chimeric entry receptors for sarbecoviruses.

Communications biology·2026
Same author

Author Correction: Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.

Nature·2026
Same author

Virological characteristics of SARS-CoV-2-related coronaviruses dynamically circulating in Southeast Asia.

Cell·2026

Related Experiment Video

Updated: Mar 13, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.1K

Modelling Ebola virus dynamics: Implications for therapy.

Alexey Martyushev1, Shinji Nakaoka2, Kei Sato3

  • 1Centre for Vascular Research, University of New South Wales, Sydney, New South Wales, 2052, Australia.

Antiviral Research
|November 8, 2016
PubMed
Summary
This summary is machine-generated.

Effective Ebola virus disease (EVD) treatment requires timely and appropriate antiviral selection. Mathematical modeling of human viral load data shows nucleoside, siRNA, and antibody therapies have specific efficacy windows for combating Ebola virus (EBOV).

Keywords:
Ebola virus infectionExperimental treatmentMathematical modelVirus dynamics

More Related Videos

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses
09:07

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses

Published on: January 20, 2017

10.7K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Related Experiment Videos

Last Updated: Mar 13, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.1K
Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses
09:07

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses

Published on: January 20, 2017

10.7K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Area of Science:

  • Virology
  • Mathematical Biology
  • Infectious Diseases

Background:

  • Ebola virus disease (EVD) is a severe, often fatal illness with no approved antiviral treatments.
  • Experimental anti-EBOV drugs show promise in animal models, but their clinical efficacy in humans is uncertain due to unknown viral replication dynamics.

Purpose of the Study:

  • To develop a mathematical model to quantitatively analyze human viral load data from the 2000/01 Uganda EBOV outbreak.
  • To evaluate the potential effects of different antiviral therapies on EVD outcomes in patients.

Main Methods:

  • Development of a novel mathematical model.
  • Quantitative analysis of human viral load data from a past EBOV outbreak.
  • In silico evaluation of different antiviral intervention strategies.

Main Results:

  • Nucleoside analogue- and siRNA-based therapies are effective if they achieve >50% inhibition and are initiated within days of symptom onset.
  • Antibody-based therapy requires a higher inhibition rate and earlier administration, particularly for severe cases.
  • The timing and potency of antiviral intervention significantly impact EVD patient outcomes.

Conclusions:

  • The choice of antiviral drug is critical for effective EVD treatment.
  • Mathematical modeling provides valuable insights into optimizing antiviral strategies for EVD.
  • Understanding EBOV replication dynamics in humans is crucial for predicting treatment success.